Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yunnan Longrun Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular health, digestive systems, and respiratory diseases, with a portfolio that includes granules, tablets, and capsules. As a subsidiary of the broader Longrun Group, it leverages Yunnan's rich botanical resources to produce standardized herbal extracts and proprietary formulations. The company is recognized for its integration of traditional herbal knowledge with modern manufacturing standards, serving both domestic and international markets. Its flagship products include Yangxue Dangui Granules and various Panax notoginseng preparations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yunnan Longrun Pharmaceutical.